Streetbeat News

Products Services

GLPG

TMO

Galapagos has entered into a strategic collaboration with Thermo Fisher Scientific to expand its decentralized CAR-T manufacturing network in the US. The financial terms of the deal were not disclosed.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 9:08 pm

TACT

TransAct Technologies Incorporated has received approval from an unnamed Quick Service Restaurant (QSR) to sell its BOHA! Terminal 2 in the US domestic market. This approval could lead to increased sales and market penetration for TransAct's product.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 9:07 pm

APLT

Applied Therapeutics announced positive topline results from its ARISE-HF Phase 3 study of AT-001, a treatment for diabetic cardiomyopathy. The study showed that AT-001 has a favorable safety profile and significantly improved cardiac function in a specific subgroup of patients not on SGLT2 or GLP-1 treatments, with a statistically significant p-value of 0.040. Additionally, AT-001 was found to prevent clinically significant worsening of the condition, with an odds ratio of 0.56 and a p-value of 0.035.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 9:06 pm

BITO

BTF

XBTF

The market is anticipating the potential impact of Spot Bitcoin ETFs on existing Bitcoin futures markets. ProShares' Simeon Hyman highlighted the maturity, liquidity, and regulation of futures markets, contrasting them with the less predictable spot markets. ProShares Bitcoin Strategy ETF (BITO), VanEck Bitcoin Strategy ETF (XBTF), and Valkyrie Bitcoin and Ether Strategy ETF (BTF) are some of the current futures ETFs. Nate Geraci and Whale Wire expressed skepticism about the benefits of spot ETFs, with Whale Wire suggesting that hype could lead to inflated prices.

Portfolio Pulse from Khyathi Dalal

January 04, 2024 | 9:03 pm

NTLA

Intellia Therapeutics, Inc. (NASDAQ:NTLA) announced its strategic priorities through 2026 and key milestones for 2024. The company ended 2023 with approximately $1 billion in cash and expects to extend its cash runway into mid-2026. Key 2024 milestones include dosing the first patient in the Phase 3 MAGNITUDE trial of NTLA-2001 for ATTR amyloidosis, initiating a Phase 3 study of NTLA-2002 for HAE, and dosing the first patient in the Phase 1 study of NTLA-3001 for AATD-associated lung disease. The company will streamline operations, resulting in a workforce reduction of about 15%. John Crowley departed from the board following his appointment as CEO of BIO.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 9:02 pm

KOPN

Kopin Corporation and MICLEDI Microdisplays have entered into an agreement to collaborate on the design, development, and manufacturing of advanced microLED displays. This partnership aims to leverage both companies' expertise in their respective fields to enhance the capabilities and applications of microLED technology.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 9:02 pm

AMZN

CMCSA

DIS

GOOG

GOOGL

NFLX

ROKU

Major streaming companies including Walt Disney Co, Roku, Comcast Corp's NBCUniversal, and Alphabet Inc's YouTube are collaborating with GroupM to streamline ad buying in streaming services. GroupM's partnership aims to innovate advertising formats as viewers shift to on-demand streaming. The initiative recognizes the need for diverse advertising strategies across different platforms like Peacock, Netflix, and Hulu. Amazon's Prime Video ad tier adds to the complexity. GroupM predicts a 14.9% increase in connected TV ad investments in North America for 2024. The consortium will work on standardizing ad formats and evaluation standards, with efforts starting in early 2024.

Portfolio Pulse from Anusuya Lahiri

January 04, 2024 | 8:36 pm

KYMR

Kymera Therapeutics' stock is trading higher following the announcement of its immunology strategy and the pipeline for its oral degraders.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 8:28 pm

NUWE

Nuwellis shares have risen following the FDA's clearance for the company's new dual lumen extended length peripheral catheter.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 8:14 pm

NUWE

Nuwellis, Inc. (NASDAQ:NUWE) has received FDA clearance for a new 12 cm dual lumen extended length catheter (dELC) for its Aquadex ultrafiltration system. This catheter provides additional venous access for treating patients with fluid overload in ICU and stepdown units. The new catheter offers the same features as the existing 16 cm version but is shorter, eliminating the need for trimming. The Aquadex system, which includes real-time hematocrit monitoring, is approved for use in adults and pediatric patients over 20 kg.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 8:12 pm